Manufacturer VerifiedIreland

Medtronic plc

Medtronic

Medtronic plc is the world's largest standalone medical device company, founded in 1949 in Dublin, Ireland. With annual revenue of $34.76 billion in fiscal 2025, the company operates 80+ manufacturing and R&D sites across the globe, employing more than 95,000 people. Medtronic is a dominant force in home medical devices, particularly through its diabetes division that generates over $2.76 billion in annual revenue from insulin pump systems and continuous glucose monitoring integration. The company's MiniMed line of insulin pumps represents the gold standard in automated insulin delivery, featuring advanced hybrid closed-loop algorithms that integrate with CGM sensors.

Strengths: Unmatched scale as the world's largest pure-play medical device company with deep R&D capabilities. Leading position in diabetes home care with the MiniMed product ecosystem. Strong regulatory expertise across FDA, CE, and global markets. Robust supply chain with manufacturing redundancy across North America, Europe, and Asia. Revenue growth acceleration with 10+ quarters of enterprise growth momentum.
Weaknesses: Diabetes division subject to intense competition from Dexcom and Insulet in the CGM and patch pump segments. Recent spin-off evaluation for diabetes business creates organizational uncertainty. Legacy product lines in cardiac and surgical segments face margin pressure from newer entrants.

Business Nature

Medtronic operates as a fully vertically integrated medical device manufacturer, controlling every stage from R&D and component manufacturing to final assembly and global distribution. Unlike many medical device companies that outsource manufacturing to contract manufacturers, Medtronic maintains over 80 proprietary manufacturing facilities worldwide, covering precision injection molding, microelectronics assembly, sensor calibration, and sterile packaging. The company's diabetes division's MiniMed production lines in Northridge, California, and Ireland represent some of the most advanced Class III medical device assembly operations globally.

Core Business Areas

Diabetes Management – Automated Insulin Delivery
• MiniMed 780G with SmartGuard hybrid closed-loop technology for automated insulin delivery
• Smart MDI multiple daily injections system with InPen smart insulin pen
• Guardian 4 continuous glucose monitoring CGM sensor with real-time glucose readings
• CareLink personal diabetes management software platform with cloud connectivity

Cardiac & Vascular – Implantable Cardiac Devices
• Micra leadless pacemaker, the world's smallest implanted pacemaker
• Resolute Onyx drug-eluting coronary stent system
• Arctic Front Advance cryoablation catheter for atrial fibrillation treatment
• Reveal LINQ insertable cardiac monitor for long-term heart rhythm surveillance

Neuromodulation – Pain Management & Movement Disorders
• Percept PC deep brain stimulation system for Parkinson's disease
• Intellis platform for chronic pain management with adaptive stimulation
• InterStim sacral neuromodulation for bladder and bowel control

Industry Rankings

1Top 10 Advanced Medical Equipment Companies

Brand

1Top 10 Advanced Medical Equipment Manufacturers & Suppliers

Mfr

2Top 10 Home Medical Devices Manufacturers & Suppliers

Mfr

2Top 10 Home Medical Devices Brands

Brand

Corporate Report

Medtronic plc is an Ireland-based medical device company headquartered in Dublin, Ireland. Founded in 1949 with annual revenue of $34.76 billion in fiscal 2025, Medtronic operates 80+ manufacturing facilities in 150+ countries with 95,000 employees.

Business Overview

Medtronic is the world's largest pure-play medical device company, with diversified operations spanning diabetes management, cardiac and vascular, neuromodulation, and surgical technologies. The company is undergoing a strategic transformation under CEO Geoffrey Martha's leadership, including the potential spin-off of its diabetes division to unlock shareholder value.

Key Strengths

• Market leadership with $34.76 billion in revenue across diversified medical device categories
• Extensive manufacturing network of 80+ facilities providing supply chain redundancy
• Diabetes division growing at double digits with MiniMed 780G and next-gen sensor pipeline
• Strong regulatory track record with FDA approvals across multiple Class III device categories
• Robust intellectual property portfolio with thousands of active patents

Challenges & Outlook

Medtronic faces intense competition in diabetes from Dexcom and Insulet in the patch pump segment. The company is evaluating a spin-off of its diabetes business, which could streamline operations but may reduce cross-divisional synergies. Global supply chain pressures and healthcare cost containment in major markets present ongoing headwinds for the company's growth trajectory.

VerityRank Score

Based on our comprehensive evaluation across all four dimensions, Medtronic achieves a VerityRank Score of 90/100, reflecting its strong position in the global home medical devices industry.

VerityRank Score

90/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Dublin, Ireland

Founded

1949

Employees

95000

Factories

80+ manufacturing and R&D sites globally across US, Ireland, Puerto Rico, Singapore

Listing

NYSE: MDT

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website NYSE: MDT , Data Sources & Methodology

Medtronic Official Website
Medtronic - Wikipedia
Medtronic Revenue - Macrotrends
Medtronic Q3 Fiscal 2026 Results
Medtronic Diabetes Spin-off - MedTech Dive

Back to Rankings